Apellis
IPO
Courageous Science + Compassion
- Headquarters
- Waltham, Massachusetts
- Employees
- 501–1000
- Founded
- 2009
- Business Model
- B2B
- Website
- apellis.com
- Total Funding
- $490.1M
- Last Round
- $350.0M Corporate RoundFeb 2023
About
Apellis Pharmaceuticals (Nasdaq: APLS) is a clinical-stage and commercial-stage biopharmaceutical company focused on the complement system, a key branch of innate immunity. Founded in 2009 by Cedric Francois and Dinesh Bhatt, the company pioneered targeted C3 inhibition with its lead compound pegcetacoplan. Apellis received FDA approval for EMPAVELI for paroxysmal nocturnal hemoglobinuria (PNH) in 2021 and SYFOVRE for geographic atrophy (GA) in 2023 — the first approved treatment for GA. Headquartered in Waltham, Massachusetts.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account